Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy.

摘要: Purpose To investigate whether primary tumor and nodal volumes defined on radiotherapy planning scans are correlated with outcome (survival recurrence) after combined-modality treatment. Methods Materials A retrospective review of patients Stage III non–small-cell lung cancer treated chemoradiation at Brigham Women's Hospital/Dana-Farber Cancer Institute from 2000 to 2006 was performed. Tumor volume measurements, as computed by Eclipse (Varian, Palo Alto, CA), were used independent variables, along existing clinical factors, in univariate multivariate analyses for association outcomes. Results For definitive chemoradiotherapy, both (hazard ratio [HR], 1.09; p Conclusions In addition traditional surgical staging disease burden, measured metastases volume, provides information that may be helpful determining prognosis identifying groups which more aggressive local therapy is warranted.